In oncology, targeted therapies are demonstrating significant promise, but only in relatively limited settings…at least so far. Nevertheless, accelerating pharmaceutical and diagnostic development has enormous potential to improve outcomes and save lives. In this paper, we explore the challenges and potential of evolving and integrating precision medicine into oncology. This paper consists of three parts:
- The Science Behind Molecular Testing
- Current Clinical Utility and Commercial Challenges
- Future Co-Evolution of Diagnostics and Pharma
